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Low-volume versus high-volume initiated
trans-anal irrigation therapy in adults with
chronic constipation: study protocol for a
randomised controlled trial
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Abstract
Background: Constipation is common in adults and up to 20% of the population report this symptom. Chronic
constipation (CC), usually defined as more than 6 months of symptoms, is less common but results in 0.5 million UK
GP consultations per annum. The effect of symptoms on measured quality of life (QOL) is significant, and CC
consumes significant health care resources. In the UK, it is estimated that 10% of district nursing time is spent on
constipation. Trans-anal irrigation therapy has become a widely used treatment despite a lack of robust efficacy
data to support its use. The long-term outcome of treatment is also unclear. A randomised comparison of two
different methods of irrigation (high- and low-volume) will provide valuable evidence of superiority of one system
over the other, as well as providing efficacy data for the treatment as a whole.
Methods: Participants will be recruited based on predetermined eligibility criteria. Following informed consent,
they will be randomised to either high-volume (HV) or low-volume (LV) irrigation and undergo standardised
radiological and physiological investigations. Following training, they will commence home irrigation with the
allocated device. Data will be collected at 1, 3, 6 and 12 months according to a standardised outcomes framework.
The primary outcome is PAC-QOL, measured at 3 months. The study is powered to detect a 10% difference in
outcome between systems at 3 months; this means that 300 patients will need to be recruited.
Discussion: This study will be the first randomised comparison of two different methods of trans-anal irrigation. It
will also be the largest prospective study of CC patients treated with irrigation. It will provide evidence for the
effectiveness of irrigation in the treatment of CC, as well as the comparative effectiveness of the two methods. This
will enable more cost-effective and evidence-based use of irrigation. Also, the results will be combined with the
other studies in the CapaCiTY programme to generate an evidence-based treatment algorithm for CC in adults.
Trial registration: ISRCTN, identifier: ISRCTN11093872. Registered on 11 November 2015. Trial not retrospectively
registered. Protocol version 3 (22 January 2016).
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Background
Burden of disease
Constipation is common in adults and up to 20% of the
population report this symptom depending on the defi-
nitions used [1–3], with a higher prevalence in women
[1, 4, 5] and older people [6, 7]. Chronic constipation
(CC), usually defined as more than 6 months of symp-
toms, is less common [8] but results in 0.5 million UK
GP consultations per annum. A proportion of the popu-
lation suffer symptoms which are both chronic and more
disabling (about 1–2% of the population) [9]. Such pa-
tients, who are predominantly female [10], are usually
referred to secondary care with many progressing to ter-
tiary specialist investigation. Patient dissatisfaction is
high in this group; nearly 80% feel that laxative therapy
is unsatisfactory [11] and the effect of symptoms on
measured quality of life (QOL) is significant [12]. CC
consumes significant health care resources. In the US in
2012, a primary complaint of constipation was respon-
sible for 3.2 million physician visits [13] resulting in
(direct and indirect) costs of US$1.7 billion. In the UK,
it is estimated that 10% of district nursing time is spent
on constipation [14] and the annual spend on laxatives
exceeds £80 million, with 17.4 million prescriptions be-
ing issued in 2012 (Health and Social Care Information
Centre, 2013) [15].
Pathophysiological basis of chronic constipation
The act of defaecation is dependent on the coordi-
nated functions of the colon, rectum and anus. Con-
sidering the complexity of neuromuscular (sensory
and motor) functions required to achieve planned,
conscious and effective defaecation [16] it is no sur-
prise that disturbances to perceived ‘normal’ function
occur commonly at all stages of life. Clinically, such
problems commonly lead to symptoms of obstructed
defaecation, e.g. straining; incomplete, unsuccessful or
painful evacuation; bowel infrequency; abdominal pain
and bloating. After exclusion of a multitude of sec-
ondary causes (obstructing colonic lesions, neurological,
metabolic and endocrine disorders), the pathophysiology
of CC can broadly be divided into problems of co-
lonic contractile activity and thus stool transit and
problems of the pelvic floor. Thus, with specialist
physiological testing (using a standard panel of radio-
physiological tests of colonic and anorectal function,
hereafter referred to as INVEST in this protocol), pa-
tients may be divided into those who have slow co-
lonic transit, evacuation disorder, both or neither (no
abnormality found with current tests). Evacuation dis-
orders can be then subdivided into those in which a
structurally significant pelvic floor abnormality is evident,
e.g. rectocoele or internal prolapse (intussusception) and
those in which there is a dynamic failure of evacuation
without structural abnormality: most commonly termed
‘functional defaecation disorder (FDD)’.
Chronic constipation management overview
Management of CC is a major problem due to its high
prevalence and lack of widespread specialist expertise. In
general, a step-wise approach is undertaken, with first-
line conservative treatment, such as lifestyle advice and
laxatives (primary care), followed by nurse-led bowel
retraining programmes, sometimes including focussed
biofeedback and psychosocial support (secondary/tertiary
care). Although these treatments may improve symptoms
in more than half of patients, they are very poorly standar-
dised in the UK and are not universally successful [17].
Thus, patients with intractable symptoms and impaired
QOL may be offered a range of costly, irreversible surgical
interventions with unpredictable results [18, 19], some-
times resulting in major adverse events (AEs) or a per-
manent stoma.
Overall rationale for the CapaCiTY programme
The current trial forms part of an NIHR-funded
programme (PGfAR: RP-PG-0612-20001). This prog-
ramme aims to develop the evidence base for the man-
agement of CC in adults which is currently lacking. This
is in contrast to the management of CC in children
for which NICE guidance has been recently published
(http://pathways.nice.org.uk/pathways/constipation/clinical-
management-of-idiopathic-constipation-in-children-and-
young-people) [20, 21]; and for adults with faecal incontin-
ence (http://pathways.nice.org.uk/pathways/faecal-incontin-
ence). Thus, the current situation is one where there are
considerable variations in practice, particularly in specialist
services. With a number of new drugs gaining or seeking
NHS approval [22–25] and technologies at a horizon-
scanning stage [18, 26, 27] it is timely that the currently
limited evidence base for adult CC is developed for
resource-constrained NHS providers to have confidence
that new and sometimes expensive investigations and ther-
apies are appropriate and cost-effective. A cost-conscious
pathway of care may help to reduce health care expenditure
by appropriately sequencing the care provided, while target-
ing more expensive therapies at those most likely to benefit.
Such data will inform the development and commissioning
of integrated care pathways. An overview of the CapaCiTY
programme is provided as a scheme (See Additional file 1)
and includes a series of interlinked work package signature
pages (WPs) that answer the important questions for pa-
tient care. A rolling programme of national recruitment will
provide a large cohort of well-defined patients for subse-
quent studies within sequential WPs over 5 years. The
focus will be on generating real-life evidence from prag-
matic studies which will provide valid clinical outcome
measures, patient acceptability and cost. Armed with such
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data it will be possible to develop an NHS management
algorithm for CC which will meet patient, clinician and
policy aims.
Specific clinical background to the prospective cohort
study of trans-anal irrigation (TAI)
Anal irrigation, using a variety of commercially available
devices, has been rapidly disseminated internationally
over the past 3–5 years, first in patients with neuro-
logical injury [28, 29] and subsequently in other CC
groups [30, 31]. Despite a lack of published data other
than from small selected case series, it is now available
on the drug tariff and generally considered to be the
next step in patients failing other nurse-led interventions
such as biofeedback. Anal irrigation has permeated the
UK market without robust efficacy data and with on-
going concerns regarding longevity of treatment and
complications [28, 32]. Retrospective clinical audit data
and review [32] suggest a continued response rate after
1 year of approximately 50% with such patients, thus
avoiding or delaying surgical intervention. An accurate
assessment of response rate and acceptability of this
intervention requires confirmation in a large prospective
cohort, together with clinico-physiological predictors of
success. In addition, two alternative systems for delivery
of TAI exist; low-volume systems delivering approxi-
mately 70 ml per irrigation, and high-volume systems
delivering up to 2 L of irrigation (although typically only
0.5–1.5 L is required per irrigation). The low-volume
system is cheaper, costing approximately £750 p.a. based
on alternate-day use, compared with approximately
£1400–1900 for high-volume irrigation, and may be
more acceptable to patients, and so a randomised study
comparing the two systems is needed.
Trial design: rationale
Robust data for the use of TAI therapy in chronic
(idiopathic) constipation are lacking. In addition, there
are no data demonstrating superiority of high-volume ir-
rigation over low-volume systems. Given the differences
in cost between the two systems, a randomised study of
well-characterised patients comparing the two methods
would provide useful information on whether one sys-
tem holds a clear advantage over the other. Also, the
short- and long-term efficacy and acceptability of ther-
apy in CC could be evaluated. This is timely and inform-
ative given the rapidly increasing popularity of this
treatment and the fact that TAI is an invasive therapy
for which patient selection should also be optimised to
maximise benefit.
In practice, patients will use one system only (plus de-
fined ‘rescue therapies’ – see below) for a minimum of
3 months. After this time point they may switch to the
other system if their initial therapy was ineffective/
unsatisfactory. Thus, consenting patients will be rando-
mised to initiate therapy with one of these systems but
will have the option of switching to the other after an
initial 3-month period. This allows us to identify re-
sponse rates to each system in the short term (3 months),
and thereafter this study is a comparison between treat-
ment strategies (low-volume initiated therapy versus
high-volume initiated therapy) rather than a pure com-
parison of the two techniques. This is a patient-centred
study design aiming to limit the time that patients spend
using ineffective therapy without being allowed to try an
alternative. This also allows estimation of comparative
cost-effectiveness of the two treatment pathways, and
whether one system works better depending on the
radio-physiological profile of the patient. Recent data es-
timates that approximately 85% of patients are still using
irrigation at 1 month; this represents a significant short-
term treatment failure rate [33]. Once patients have
switched therapy, they may not switch back to the first
system; once they have tried both systems and discontin-
ued them then they will be considered to have com-
pleted the intervention and they will return to routine
clinical care.
Irrigation is a maintenance therapy rather than a cure.
In addition to outcome measures of the Patient
Assessment of Constipation Quality of Life question-
naire (PAC-QOL) [34, 35] score at 3 months, patients
will provide survival data (time until cessation of irriga-
tion therapy due to lack of benefit). Switching systems
does not affect this; the survival data is based on the use
of irrigation irrespective of system. A survival analysis is
appropriate since anal irrigation is time-consuming and
inconvenient as a therapy and patients may find the
process distasteful. Patients are unlikely to continue with
treatment if they are not gaining worthwhile benefit
from it; treatment continuation is a useful patient-
centric assessment.
Consideration of the findings from both groups
(individually and together) will be used to model the net
value to patients of anal irrigation, considering persist-
ence of benefit.
Risks/benefits
The interventions proposed are those already offered to
patients in specialist centres throughout the UK and
internationally. All interventions pose acceptable and
minimal risks. For instance, the only invasive tests
(INVEST) have been performed daily in most specialist
centres for up to 30 years without any recorded compli-
cation (Barts Health experience of over 10,000 patients).
A small ionising radiation dose is required for one of the
tests (covered below). A number of questionnaires
contain personal questions about bowel problems and
the effect of these on QOL and psycho-behavioural
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functioning; however, all have been used in studies of
similar patients previously.
Trans-anal irrigation has been shown to be a low-
risk intervention and is widely used in a variety of
defaecatory disorders such as neurogenic bowel dys-
function, idiopathic constipation and faecal incontin-
ence. Serious adverse events (SAEs) are rare, with one
study reporting two nonfatal bowel perforations out
of approximately 110,000 irrigation treatments [28].
Other potential side effects include pain, bleeding,
painful haemorrhoids and anal fissure. A recent study
reported an overall adverse event (AE) rate of 22%
when all minor and reversible events were considered.
Thirteen percent reported technical problems with
equipment and 13% reported minor side effects/AEs
[33]. The risk of nonparticipation is considered very
low.
The benefits of participation are that patients will re-
ceive a very high standard of monitored care as a conse-
quence of the detailed protocol. Participation will inform
future treatment options for patients with CC.
Trial objectives
Primary objectives
1. To compare the impact upon patient disease-specific
QOL of TAI initiated with a low-volume versus a
high-volume system in patients with CC, measured
at 3 months
Secondary objectives
To determine:
1. Survival (continuation of benefit) and acceptability
in the longer term (up to 12 months)
2. Disease-specific outcomes at 1, 3, 6 and 12 months
3. The influence of patient characteristics (urge to
defaecate, balloon sensory testing results) upon
treatment success, and response by type of system
used
4. The acceptability of each system to patients
5. Strategies for tailoring therapy to meet patients’
individual needs, and the factors involved in this
6. The safety of each system and prospective tracking
of AEs
7. The cost-effectiveness of care
8. Qualitatively evaluation of patient and health
professional experience
Methods
Setting
Specialist centres across the UK with a mix of urban and
rural referral bases
Recruiting sites (initial)
 Barts Health NHS Trust [Allison]
 St. Mark’s Hospital at London North West
Healthcare NHS Trust [Vaizey]
 University College Hospital London [Emmanuel]
 Guys and Thomas’ Hospitals London [Williams]
 Sandwell and West Birmingham NHS Trust [Gill]
 County Durham and Darlington NHS Foundation
Trust [Yiannakou]
 University Hospital Southampton NHS Foundation
Trust [Nugent]
 Norfolk and Norwich University Hospitals NHS
Foundation Trust [Speakman]
 University Hospital of South Manchester NHS
Foundation Trust [Telford]
 Sheffield Teaching Hospital NHS Foundation Trust
[Brown]
 North Bristol NHS Foundation Trust [Dixon]
 University Hospitals Bristol, NHS Foundation Trust
[Mabey/Randall]
 Newcastle Upon Tyne, NHS Foundation Trust [Plusa]
 Homerton University Hospital, NHS Foundation
Trust [Cuming]
Reserve sites
 University Hospital Leicester NHS Foundation Trust
[Miller]
Central facilities
 Bart’s and the London, Pragmatic Clinical Trials
Unit. Centre for Primary Care and Public Health,
Queen Mary University London (QMUL)
 County Durham and Darlington NHS Foundation
Trust, Durham Clinical Trials Unit. Wolfson
Research Institute, Durham University
Inclusion criteria
 Age 18–70 years
 Patient self-reports problematic constipation
 Symptom onset more than 6 months before
recruitment
 Symptoms meet American College of
Gastroenterology definition of constipation
 Nonresponse to constipation treatment to a
minimum basic standard (see NHS Map of
Medicine 2012) [36]: Comprising lifestyle and
dietary measures and two or more laxatives or
prokinetics tried (no time requirement)
 Ability to understand written and spoken English
(due to questionnaire validity)
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 Ability and willingness to give informed consent
 Failure of previous nurse-led behavioural therapy
 Ability of patient/carer to use anal irrigation
The study will use the American College of Gastro-
enterology definition of constipation [37] (which is
reasonable, simple and extensively published): unsatisfac-
tory defaecation characterised by infrequent stool, difficult
stool passage or both for at least previous 3 months. This
avoids the more complex Rome definitions.
Exclusion criteria
The study interventions necessitate the exclusion of
major causes of secondary constipation. In detail:
 Significant organic colonic disease (‘red flag’
symptoms, e.g. rectal bleeding previously investigated);
inflammatory bowel disease (IBD); megacolon or
megarectum (if diagnosed beforehand) (the study will
provide a useful estimate of the prevalence of such
cases in referral practice); severe diverticulosis/
stricture/birth defects deemed to contribute to
symptoms (incidental diverticulosis not an exclusion)
 Major colorectal resectional surgery
 Current overt pelvic organ prolapse (bladder, uterus,
vagina, rectum) or disease requiring surgical
intervention
 Previous pelvic floor surgery to address defaecatory
problems: posterior vaginal repair, STARR and
rectopexy; previous sacral nerve stimulation
 Previous use of TAI therapy to treat constipation
 Rectal impaction (as defined by digital and
abdominal examination: these form part of the NHS
Map of Medicine basic standard) [36]
 Significant neurological disease deemed to be
causative of constipation, e.g. Parkinson’s disease,
spinal injury, multiple sclerosis, diabetic neuropathy
(not uncomplicated diabetes alone)
 Significant connective tissue disease: scleroderma,
systemic sclerosis and SLE (not hypermobility alone)
 Significant medical comorbidities and activity of
daily living impairment (based on Bartell index in
apparently frail patients [38], Barthel Index ≤11)
 Physical disability/impairment which prevents the
use of one or other of the irrigation devices
 Major psychiatric diagnosis (schizophrenia, major
depressive illness, mania, self-harm, drug/alcohol
addiction)
 Chronic regular opioid use (at least once daily use)
where this is deemed to be the cause of constipation
based on temporal association of symptoms with
onset of therapy; all regular strong opioid use
 Pregnancy or intention to become pregnant during
study period
Note: ‘red flag’ symptoms are not an exclusion if they
have been investigated before enrollment and organic
disease excluded. Previous TAI therapy does not include
private (non-NHS) ‘colonic irrigation’ therapy; prior use
of such treatments is not an exclusion criterion.
Study interventions: trans-anal irrigation therapy
Trans-anal irrigation training will be provided by trained
nurse or physiotherapist with experience in delivering care
for CC. They must have initiated irrigation therapy in at
least three patients independently, and be a nurse/therapist
of good standing within a clinical team regularly seeing pa-
tients with CC. A standardised approach and intervention
will be provided via the use of an intervention manual. For
the first 3 months of participation in the study, patients
may not use other therapies besides anal irrigation and
those rescue therapies specified below. They may discon-
tinue therapy at any point (elective withdrawal from inter-
vention) and may switch from one system to the other
after 3 months. Switching anal irrigation systems before
completing the 3-month waiting period will be discour-
aged. If it does occur, it will be documented as a protocol
deviation with the timing and reason documented. If
symptoms are severe despite the use of irrigation and res-
cue therapies then other medications may be used on com-
passionate grounds, but this must be recorded in the Case
Report Form(CRF)/concomitant medications log.
The course of therapy will include a nurse-led training
session (or more if required to ensure that the device is
being used effectively) followed by patient-led home irri-
gation therapy. The low-volume system commonly used
in practice is Qufora® Mini (MBH-International). Various
high-volume systems are used, all of which have very
similar mechanisms of action; these include Peristeen™
(Coloplast) and Qufora Toilet/Qufora Balloon™ (MBH-
international). These are commercially available TAI sys-
tems available on prescription in NHS practice.
Low-volume irrigation
This system consists of a small reservoir attached to a
cone. The reservoir holds approximately 70 ml of water
and is squeezed to inject water into the rectum. The re-
gime used will be as follows: initial irrigation once daily
for 14 days using one to three insufflations (each of 70 ml
approximately). This may then be reduced to alternate
days depending on response. Patients may then adjust fre-
quency and volume depending on response. They may ir-
rigate as much and as often as they feel is necessary to
give them benefit and this information will be captured on
the CRF with the aid of an Irrigation Journal.
High-volume irrigation
High-volume systems consist of an irrigation bag con-
nected to a tube. The water flows into the rectum,
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either by gravity or using a pump. Some systems em-
ploy a balloon to hold the device in place during irri-
gation; others require the patient to hold it in place.
The mechanism of action is the same for all systems.
Initial frequency of irrigation is the same as for low-
volume irrigation; i.e. daily for 14 days, then alternate
days. Patients will commence with irrigations of
300 ml and increase this by 100 ml every 2 days until
satisfactory defaecation is achieved or the procedure
becomes uncomfortable, up to a maximum of 1500 ml.
Patients may adjust therapy depending on response, as for
low-volume irrigation.
Switching between anal irrigation systems
After 3 months of using one system, patients may
switch to the other or discontinue therapy and return
to routine clinical care. This will be entirely patient-
led, and reasons for changing systems will be ex-
plored during follow-up visits and captured on the
CRF. There is, therefore, no defined protocol for
switching treatments as patients may do this for any
reason; analysis of time to switching/discontinuing
therapy, as well as the patient-reported reasons for
doing so, will provide insight into why each irrigation
system is or is not successful. In addition, qualitative
interviews with patients who have switched or discon-
tinued therapy will be used to explore these issues
more deeply.
Endpoints
Clinical endpoints
All clinical endpoints will be in common with a single
standardised outcome framework (consistently used
within all CapaCiTY programme studies). All outcomes
will be recorded at baseline, 3, 6 and 12 months in face-
to-face clinics (or by telephone call if necessary). PAC-
QOL, the Patient Assessment of Constipation Symptoms
(PAC-SYM) and the EuroQol Health Outcome measure
(EQ-5D-5 L) and the EuroQol Visual Analogue Scale
(EQ-VAS) will additionally be collected at 1 month; this
is to capture reasons for early nonresponse to therapy,
as well as to better characterise the patient group and
provide more data for economic analysis. The primary
endpoint will be at 3 months.
Primary clinical outcome
 Patient Assessment of Constipation Quality of Life
questionnaire (PAC-QOL [34, 35]) at 3 months.
Secondary clinical outcomes
 PAC-QOL score and individual domain scores at 1,
3, 6 and 12 months
 Time to cessation of each system of irrigation; total
time in treatment with either system (from Irrigation
Journal) at 1, 3, 6 or 12 months
 Reason for cessation (of each system) (Irrigation
Journal and qualitative interviews) at 1, 3, 6 and
12 months
 Patient Assessment of Constipation Symptoms
(PAC-SYM): aggregate and domain scores at 1, 3, 6
and 12 months
 Volume and duration of irrigation (Irrigation
Journal) at 1, 3, 6 and 12 months
 Number and nature of bowel motions (captured in
2-week Patient Diary) at 3, 6 and 12 months
 Symptom scores derived from Diary records (taken
over 2 weeks before or around each follow-up
contact. These will include number of spontaneous
complete bowel motions at 3, 6 and 12 months
 Generalised Anxiety Disorder Questionnaire
(GAD-7) at 3, 6 and 12 months
 Depression, anxiety and somatisation modules of the
PHQ-9 at 3, 6 and 12 months
 Global patient satisfaction/improvement score
(Visual Analogue Scale; VAS) at 3, 6 and 12 months
 Patient acceptability and recommendation to other
patients (qualitative interviews)
 Behavioural Response to Illness Questionnaire (CC-
BRQ) and Brief Illness Perception Questionnaire
BIPQ (CC) at 3, 6 and 12 months
 Generic quality of life: EuroQol EQ-5D-5 L and EQ-
VAS scores 1, 3, 6, and 12 months
 Use of health care resources, AEs, and concomitant
medications (collected using Patient Journal) at 3, 6
and 12 months
Health economic outcomes
 Interventions, treatment sequelae and other
health resource use related to the care of CC will
be recorded in natural units and cost applied
where possible using national reference costs.
Additionally, patient costs related to constipation
and the opportunity cost of time away from
normal activities will be valued using national
reference sources.
Patient experience (see ‘Qualitative interviews’)
 Face-to-face, digitally recorded, semistructured
interviews will be conducted involving a
purposive, diverse sample of patients throughout
the programme, with participants reflecting a
range of ages, geographical locations and, where
possible, other pertinent attributes, such as
ethnicity and gender, continuing until data
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saturation when no new themes emerge.
Participants will be approached by a member of
the research team and will undergo a separate
consent process if they are willing to participate
in the qualitative study.
Study design/plan – Study visits
The following section provides an overview of patient
study visits. This is provided in diagrammatic format in
the attached Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) figure (Fig. 1. See
Additional file 2 for the SPIRIT Checklist).
Visit 0: Prescreening: eligibility assessment
A Good Clinical Practice (GCP)-trained and dele-
gated local researcher will screen for basic eligibility
by telephone (or face-to-face interview based on pa-
tient choice). Potentially eligible patients will be
identified either in clinic, from referral letters from
GPs/other consultants to the constipation clinic, and
from patients participating in CapaCiTY 01 who did
not respond, or have ceased to respond, to habit
training (HT)/biofeedback (HTBF). Participants will
be provided with adequate explanation of the aims,
methods, anticipated benefits and risks of anal irriga-
tion therapy and will take away or be posted an invi-
tation letter and a Participant Information Sheet
(PIS). Patients will be given at least 24 h to consider
participation and invited to attend clinic for visit 1
(see below).
The study screening number will be allocated as
follows:
 Study code 02
 Site code – three-letter code for each site
 Participant Code – four-digit code given consecutively
and attributed at each site
For example, the first participant recruited at Barts
Health Trust would be assigned the code 02-BLT-0001.
Patients progressing to other studies within the
CapaCiTY programme will keep this number for path-
way tracking.
Visit 1: Screening, consent, baseline assessments and
randomisation
Visit 1 will be conducted face to face in clinic. Following
a detailed discussion about the trial, potentially eligible
and agreeable patients will complete a written informed
consent, followed by a more thorough screening and
confirmation of eligibility for randomisation by standar-
dised medical and surgical history and physical examin-
ation (the latter if not already performed within the
previous 3 months).
Patients who decide not to opt for treatment will
be invited to offer reasons and these will be recorded
when provided. Patients declining participation will
continue to receive usual care as locally provided.
There is no obligation for patients to give reasons for
nonparticipation.
*V1.1 = INVEST – A minimum timeframe of 2 weeks to allow completion of baseline diary prior to INVEST and maximum of 8 weeks (for logistical purposes). 
V2 = commencement of therapy and TAI training; V2.1 = Phone call within 2 weeks 
**V2.2 = further training if needed to be conducted prior to or in conjunction with V3 if necessary. V3 = 4 week follow up session (Face-to-face if possible or telephone)
All follow up time points measured from commencement of therapy (V2)
*** Resource use data is collected in patient journal training and retrospective completion of this journal occurs at visit 1.
Assessment V0
Pre-Screening
V1
Screening & 
Baseline
V1.1: INVEST*
V2
Intervention 
assessments
V2.1 (V2.2**) 
Intervention 
assessments
V3
1 month 
intervention FU 
review
V4
3 month FU 
visit
V5
6 month FU 
visit
V6
12,month
FU visit
Minimum Timeframe between visits+
(Maximum Timeframe)
-1 day 0 +2 weeks(+ 8 weeks)
+ 2 weeks
(+/- 3 days)
+2 weeks
(+/- 1 week)
+ 2 months
(+/-1 week)
+ 3 months
(+/-1 week)
+ 6 months 
(+/-1 week)
Brief screening and providing PIS x
Informed Consent x
Structured history including eligibility assessment, 
demographics, medical history, medications, clinical 
examinations 
x
Pregnancy Test where applicable x
Baseline only assessments x
Rectal balloon sensory testing* x
Balloon expulsion test* x
Anal manometry* x
Radio-opaque marker transit study* x
Randomisation x
In therapy assessments (Anal Irrigation)** x x x
Standardised outcome framework assessments x x x x
Short Outcome Assessment x
Patient Diary Provided x x x x
Patient Diary Collected *** x x x x
Patient Journal Provided X
Patient Journal Collected x x x
Irrigation Journal Provided x x x x
Irrigation Journal Review x x x x
Adverse Event and Concomitant Medication Review x x x x x x x
Fig. 1 SPIRIT figure (schedule of assessments)
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For those patients entering the study, additional base-
line outcome assessments will be conducted. These in-
clude several key validated assessments that profile
patient characteristics, informing disease pathophysi-
ology and potential predictors of treatment response. All
have been selected on the basis of trade-off between ad-
equate detail and achievable brevity. These instruments
will be combined with the standardised outcome frame-
work into a single booklet (design and presentation have
been optimised by patient representatives).
Confirmation of eligibility
 Standardised history by interview including previous
medication usage
 Clinical examination findings (carried forward if
performed previously within last 3 months):
standardised exam of perineum/anus/rectum
Baseline outcome assessments
 Baseline outcome assessments (PAC-QOL, PAC-
SYM, EQ-5D-5 L and EQ-VAS, PHQ-9, GAD-7,
CC-BRQ and BIPQ-CC, see endpoints above)
 Baseline 2-week Patient Diary will be given. Training
in completion of the diary will be conducted at visit
1 and the diary will be completed at home and
returned at visit 2
 Training and retrospective completion of the Patient
Journal will occur at visit 1 for collection of resource
data. Prospective completion will occur continuously,
with review at each follow-up visit from 3 to
12 months
Other baseline only assessments
 Constipation (2006) and IBS (2006) modules of the
Rome III Questionnaire
 Cleveland Clinic Constipation Questionnaire
 Brief, chronic pain, autonomic and joint
hypermobility assessments
 St. Mark’s Incontinence Score (for concurrent
symptoms)
Randomisation
Conducted by a member of the research team.
INVEST radio-physiology investigations
There is no defined time period for this, but it is sug-
gested that INVEST should be completed within 4 weeks
of the visit 1 baseline visit to allow for diary completion
before stopping laxatives for INVEST. A maximum of
8 weeks is tolerated to conduct INVEST. Those with
INVEST completed in the previous 12 months do not
need these repeated and can be booked for visit 2, com-
mencing in a minimum of 2 weeks to allow completion
of the baseline diary.
Training sessions (45–60 min) (V2–V3)
This will use a standardised proforma and will always be
face to face. Patients will receive:
Visit 2: First training session
Visit 2.0
1. Collection of baseline diary completed before
stopping laxative (i.e. before INVEST in patients
who need this done)
2. Training in TAI: patients will undergo a single,
nurse-led training session before starting treatment.
The device will be demonstrated to the patient by
the nurse specialist and then the patient will practice
setting up the device. The trainer will ensure that
the patient knows how to use the device correctly
before home irrigation is commenced
3. Training in completion of the Irrigation Journal and
provision of the Irrigation Journal to be completed
weekly. The Irrigation Journal consists of: volume of
water introduced, frequency of use, AEs and side
effects, e.g. pain, bleeding
4. The trainer and patient will agree a date for delivery
of equipment and commencement of home irrigation.
Ideally, this should be the same as the first training
visit, but this may not be possible due to delay in
supplying irrigation equipment. Any delays should be
recorded on a deviation log/note to file (CRF 7/8) to
allow data analysis to be adjusted accordingly
5. Start date for home irrigation agreed with the
patient (this is to allow for any delay in delivery of
equipment). Ideally this should be the same day as
visit 2, or within 1 week maximum. If any issues or
delays have been encountered, a new commencement
date is agreed; this should be recorded as a deviation/
note to file (CRF 7/8), along with reasons for delay
6. Regulation/standardisation of laxative use: bisacodyl
may be used orally as a rescue therapy (up to 20 mg
at night), plus glycerine suppositories, one or two, if
needed, if no stool for 3 days. In addition, patients
may take Movicol up to a maximum dose of two
sachets three times per day (TDS) and/or lactulose
up to 15 ml twice per day (BD). Prokinetic drugs
and any other drug that the British National
Formulary (BNF) describes as having laxative effect
or herbal teas that contain strong purgatives will be
discouraged, but if needed (i.e. if symptoms severe)
then these are permitted but use must be recorded
in the concomitant medications log. There will be
no use of enemas.
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Visit 2.1: First intervention assessment
A telephone call will be made to the patient 14 days
(±3 days) after visit 2 to check that everything is pro-
ceeding correctly and to resolve any problems. If, due to
delay in obtaining equipment, etc., the patient has not
started irrigation at this time then the telephone call
(and other follow-up visits) should be rescheduled for
14 days later, and the reason for this recorded on CRF
7/8. Adverse events and concomitant medications will
also be reviewed.
Visit 2.2: Second intervention assessment (if needed)
If there are problems then a further face-to-face training
session will be offered, including a review of AEs and
concomitant medications. This can occur any time be-
fore visit 3 (2 weeks ±1 week from visit 2.1) or in con-
junction with visit 3 if not before.
Patients will continue the self-administered therapy
using a commercially available device until the end of
the study. Patients will be followed up until the end of
the data collection phase of the study (variable follow-up
12–24 months depending on date of recruitment) or
until they decide to discontinue either the therapy or the
trial follow-up. Irrigation will be performed at an agreed
frequency initially. Once established on this therapy pa-
tients may adjust the frequency and volume of irrigation
to suit their particular condition.
Information about treatment will be recorded in the
Irrigation Journal. Where a patient switches to the other
irrigation device or discontinues treatment (patient
choice) the reason for this, as well as the duration of
therapy, will be documented. If a patient chooses to
switch devices, which they may do at any stage after the
3-month follow-up visit, they will receive training in the
other device. They will receive a follow-up by the irriga-
tion nurse as required to resolve any outstanding issues
and to check progress. This should be documented on
the Irrigation Journal and a note to file, (CRF 8) and
change/discontinue, (CRF 12) should be completed.
However, they will not be asked to repeat the question-
naires and diaries already completed at 1 and 3 months.
Visit 3: 1-month follow-up review
1. All patients will receive a further training assessment
at 2 weeks (±1 week) after visit 2.1, allowing for any
delay as described previously (V3). This visit will be
combined with collection of PAC-QOL, PAC-SYM
and EQ-5D-5 L and EQ-VAS and should be face to
face. The Irrigation Journal will be reviewed at this
visit. A telephone call is an acceptable alternative if
this is not possible
2. Standardised guidance on how to tailor therapy to
each patient depending on initial response will be
provided to specialist nurses/therapists. Changes in
regimen, as well as system, will be documented on
the CRF. As outlined previously, switching between
irrigation systems before the 3-month visit is
discouraged, and represents a protocol deviation.
However, it is recognised that some patients may
need to switch systems before 3 months: if this
occurs it must be recorded on CRF 12 and on the
deviation log. Primary outcome analysis at 3 months
will be by intention-to-treat
Telephone support will be available from the therapist
between visits (number given, office hours only). The
therapist will complete the intervention CRF at every
visit or patient contact. For contact with patients after
the training period, a note to file (CRF 8) should be
completed, and the patient will also make a note of any
contact in their Irrigation Journal. In the instance of new
psychological issues being determined during consult-
ation, referral for psychological support will be deferred
until after completion of irrigation training. The excep-
tion to this rule would be where there is clinical concern
regarding the patient’s acute mental state requiring more
urgent intervention (see ‘Criteria for withdrawal from
treatment’). Concerns would be raised by the irrigation
nurse team to the research team, and these would be
evaluated by the principal investigator (PI) (or a medic-
ally trained deputy) and appropriate action taken. Fur-
ther follow-up visits (V4–V8) will be conducted by the
research team. If the patient requires further input from
the irrigation nurse this may be arranged as per local
practices. Any contact and any changes made or advice
given regarding irrigation should be recorded in the
Patient Journal and the Irrigation Journal.
Visits 4–6: Follow-up outcome assessments: visits or
telephone consultations
A full, standardised outcome framework and health eco-
nomic dataset will be recorded at baseline, 3, 6 and
12 months (±1 week) after initiation of intervention at
visit 2. To maximise completeness of data collected,
follow-up visits will be conducted face-to-face in clinic
wherever possible. Where this is not possible, a tele-
phone consultation will be used. The Patient Diary and
Journal and Irrigation Journal will be provided for review
at each follow-up visit.
Patients deciding to switch to the alternative system
will be trained in the new system by the irrigation nurse
and this will be recorded on the note to file, CRF 8 and
change/discontinue, CRF 12. These patients will not
need to complete the questionnaires at 1 month and
3 months if they have already done so.
Within the follow-up period at least three attempts via
two different methods (e.g. telephone and letter), will be
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made by research staff to make contact and collect
follow-up data at each time point, after which the time
point will be recorded as missing.
Recruitment and strategies for achieving enrollment
Patients attending specialist centres (outpatient clinics,
gastrointestinal (GI) physiology units) for constipation
and who have already failed to respond to a minimum
basic standard of treatment (see above), as well as nurse-
led interventions (biofeedback or habit training), will be
eligible for recruitment screening based on criteria. Pa-
tients will be recruited from those failing treatment in
CapaCiTY 01 but also those patients seen outside the
trial who have had nurse-led behavioural therapies with-
out response.
Trial posters will be displayed in primary care, phar-
macy and community care settings, directing patients to
their nearest research site and contact person, as well as
the study website for more information, including the
PIS. The same posters may be used to advertise the
study via newspapers, trial websites, social media, and
patient groups such as Bowel and Cancer Research
charity.
Patient and Public Involvement (PPI) consultation
with CC patients in secondary care has explored the ac-
ceptability of this study design, and we have found that
this is likely to be acceptable to patients. The proposed
rescue therapy and patient diaries/journals used in the
study have been reviewed as part of this process. Care
has been taken to ensure that the study design is
patient-centred, with flexibility of laxative use incorpo-
rated into the protocol, as well as the option to switch
treatment after 3 months. This aims to ensure that pa-
tient experience of the trial is similar to a nontrial
patient in terms of treatment received, within the con-
straints of a randomised trial.
Study procedures
Screening, enrollment
A brief screening questionnaire will be used to determine
whether patients meet the inclusion and exclusion criteria
(see ‘Eligibility’ above). Screening will be performed by
suitably trained study personnel to minimise logistic hur-
dles, and as determined by geographic availability.
The brief screening questionnaire will also be made
available on the study website, with the PIS for patients to
self-screen and contact their nearest research site if inter-
ested in taking part. All basically eligible participants will
then undergo a formal face-to-face consent, screening and
enrollment session prior to randomisation.
Randomisation procedures
Patients will be randomised 1:1 into two groups; those
who commence therapy with a low-volume device and
those starting with a high-volume device. Patients will
be stratified by sex and women by centre. Randomisa-
tion will be performed by a GCP-trained member of the
research team using a bespoke, secure online system de-
veloped by the Pragmatic Clinical Trials Unit (PCTU).
Blinding
Patients and clinicians are necessarily aware of both
INVEST and treatment allocations. The need to collect
data on frequency and volume of irrigation, as well as
reasons for discontinuing or switching between systems,
means that assessor blinding is not possible with respect
to these outcomes. Those involved in the development
of the statistical analysis plan (SAP) will not have access
to any data that will lead them to become unblended
and, therefore, they will remain blind. Any researcher
collecting CRFs, handling journals or performing statis-
tical analysis on the above outcomes will be unblinded.
However, in order to control for observer bias, the pri-
mary outcome (PAC-QOL at 3 months) will be con-
cealed; the patients will complete this questionnaire
without a researcher present. This will be accomplished
in one of the following ways:
1. Direct entry to online secure database, with built-in
validation and prompting to ensure data
completeness
2. Completing paper questionnaire by following
instructions on an information card to ensure that
all questions are answered. This will be placed in a
sealed envelope marked with the patients
pseudonymised study code and will not be opened
until the time comes for data entry
Radio-physiological investigations (INVEST)
Patients will undergo standardised investigations. If
INVEST previously conducted within the last 12 months,
results can be carried forward. Pregnancy testing will be
conducted as per routine NHS practice (10-day NHS
rule) in respect to women between menarche and meno-
pause. Women of equivocal status will have a pregnancy
test performed as per routine care.
1. Anorectal manometry using standard or high-
resolution methods [39–41], depending on local
availability, to determine defined abnormalities of
recto-anal pressure gradient during simulated
evacuation [42–44]
2. Balloon sensory testing using standardised methods
[45, 46] (2 ml air per second to maximum 360 ml)
to determine volume inflated to first constant
sensation, defaecatory desire and maximum
tolerated volumes. Rectal hyposensation and
hypersensation, defined in accord to gender-specific
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normative data on 91 healthy adults [47]. The recto-
anal inhibitory reflex (RAIR) will also be elicited by a
50-ml rapid inflation (if necessary in 50-ml aliquots
up to 150 ml)
3. Fixed volume (50 ml) water-filled rectal balloon
expulsion test [42, 43, 48, 49] in the seated position
on a commode. Abnormal expulsion is defined as
abnormal if failure to expel with a 1-min effort for
men and 1.5 min for women [50]
4. Whole gut transit study using serial (different
shaped) radio-opaque markers over 3 days with a
single plain radiograph at 120 h [51, 52]
Note: INVEST procedures conducted prior to recruit-
ment to the study (i.e. within the past 12 months) may
be done using locally available devices and methods.
All patients will undergo TAI therapy irrespective of
INVEST results, and will be followed up in the same
way. The purpose of INVEST in this study is to identify
whether certain radio-physiological results correlate with
treatment response, i.e. can we predict likelihood of
benefitting from irrigation based on pretreatment inves-
tigations. Balloon sensory testing in combination with
patient-reported urge to defaecate will be analysed as co-
variates to determine whether such a relationship is
present.
Concomitant medications
It is inevitable that patients will seek recourse to laxa-
tives and other dietary supplements during the course of
the programme. Experience shows that complete prohib-
ition can lead to unreported laxative use, which might
confound findings. Although we will strongly discourage
ad libitum medication usage and specify a defined break-
through regimen, we will record cotreatment with suffi-
cient fidelity and integrity to enable use as covariates in
analyses using a specific patient journal for this purpose
(see ‘Standardised outcome framework’). A concomitant
medications list, including a shortlist of contributory or
confounding medications, will be used to filtre on data
entry. Patients using one system in the medium/long
term may wish to revert to the other system or pause
treatment for a short period (for example, while going
on holiday) for practical reasons. This is permitted but
must be recorded in the concomitant medications log.
This will not be considered as switching or ending treat-
ments as it is only a short-term measure.
Criteria for discontinuation
The interventions proposed are well-established in
current clinical practice. There are no defined criteria
for discontinuation; however, clinicians may withdraw
treatment where they have therapeutic or safety con-
cerns, consistent with routine care. Patients may choose
to discontinue treatment at any point and return to rou-
tine clinical care.
Procedure for collecting data including Case Report
Forms (CRFs) and storage
The data collected for the trial will be a mixture of
routinely collected data, verifiable against the medical
record and patient-reported outcome (PRO) or question-
naire data, collected directly to CRF.
Each recruiting site will be required to keep accurate
and verifiable source notes in the medical record rele-
vant to each study participant’s inclusion and continued
participation in the study. Data will be collected, trans-
ferred and stored in accordance with GCP guidelines
and data protection requirements. The PCTU standard
operating procedures (SOPs) and study data manage-
ment plan will define the exact process of data collec-
tion, transfer and storage and control of study data.
A secure online OpenClinica trial database will be pro-
vided by the PCTU to enable remote data entry at sites
where this is feasible. This database will provide built-in
data-validation checks with quality control (QC) checks
performed by checking a predefined percentage of CRF
data against data entered into the database. In addition,
on-site monitoring will enable source document verifica-
tion (SDV) of records.
Patient-reported outcome measures (PROMs), includ-
ing questionnaires and diaries, may be collected directly
to the eCRF using a secure and controlled REDCap
database. An automated email reminder will be sent to
participants to remind them to complete the question-
naires and diaries every 12 weeks. Alternatively, partici-
pants can complete paper questionnaires and diaries to
be entered by the central study team.
All patient-identifiable data, such as Consent Forms,
screening and identification logs will be stored in the in-
vestigator site files in secure locked cabinets and/or of-
fices, accessible only to delegated members of the study
team. Secure methods of data transfer will be used to re-
turn CRFs to the coordinating site for centralised data
entry, monitoring, QC in compliance with GCP. A copy
of the CRF will be held at the site in accordance with
GCP.
Follow-up procedures
The study duration allows for follow-up to a maximum of
12 months with data collection at 3, 6 and 12 months post
initiation of therapy. Primary outcome data will be col-
lected at 3 months. Each participant will have a minimum
of 3, 6 and 12 months’ follow-up data for collecting the pri-
mary and secondary outcomes. In addition, PAC-SYM,
PAC-QOL and EQ-5D-5 L and EQ-VAS will be recorded
at the 1-month visit; this is to capture information on early
nonresponders and to better understand and characterise
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this group of patients. Participants will leave the study and
return to ‘routine clinical care’ as determined within their
local NHS institution (or be recruited to subsequent trials).
Alternatively, they may wish to proceed to enrollment in
the next WP (study 3 – Laparoscopic Ventral Mesh
Rectopexy) within the CapaCiTY programme.
The following data will be collected at each visit up to
12 months
 Validated symptom and QOL questionnaires (PAC-
SYM and PAC-QOL). Validated generic QOL ques-
tionnaires: EQ-5D-5 L descriptive system and EQ-
VAS. Note: EQ-VAS has a standard deviation (SD)
of approximately 30 points: a 10% difference in VAS
deemed clinically significant can be detected with
the large sample sizes proposed
 Patient Health Questionnaire-9 (PHQ-9) [53–55]
 Generalised Anxiety Disorder Questionnaire
(GAD-7) [56]
 Depression, anxiety and somatisation modules of the
Patient Health Questionnaire [53–56] and the Illness
Perception Questionnaire [57]
 Global patient satisfaction/improvement score
(VAS) and whether they would recommend each
treatment experienced to other patients
 Potentially modifiable cognitive and behavioural
psychological variables shown to predict onset and
perpetuation of other functional bowel symptoms:
negative perfectionism, avoidant and ‘all or nothing’
behaviour subscales of the Behavioural Response to
illness Questionnaire (CC-BRQ), and the Brief
Illness Perception Questionnaire BIPQ (CC)
 A 2-week Patient Diary (for 2 weeks prior to each
assessment at 3, 6 and 12 months) to record bowel
frequency and whether each evacuation was
spontaneous (no use of laxatives) and/or complete;
the patient journal will also capture concurrent
medication, health contacts, and time away from
normal activities (including work). Patients will be
contacted by telephone to remind them to start the
diary. If a patients forget to do this, then it is
acceptable for them to start recording the diary on
the day that they are seen in clinic and for this to be
collected 2 weeks later
 Resource use data (using patient journals as a
prompt and including concomitant medication use)
 Irrigation Diary to record frequency and volume of
irrigation and any AEs
Laboratory assessments
Serum or urine pregnancy testing may be performed as
per standard care for any women of equivocal status
undergoing radiological assessments (INVEST).
Radiology assessments
The whole gut transit study usually (90% patients) in-
volves the use of a single, plain abdominal radiograph
(in 10% patients, a maximum of two may be required to
image the whole abdomen and pelvis). This procedure
forms part of routine clinical care for patients with CC
at many NHS centres. All practitioners (radiologists,
radiographers, etc.) directing these studies will hold ap-
propriate IR(ME)R certification.
Participant withdrawal (including data collection/
retention for withdrawn participants)
Individual participants will be able to withdraw from treat-
ment at any time by notifying health care professionals in-
volved with the study, and return to routine care without
prejudice. Data will be retained for analysis from all partic-
ipants after the point of consent and recruitment.
Criteria for withdrawal from treatment:
Participant develops any of the following exclusion criteria
 Participant becomes pregnant or intends to become
pregnant (only in baseline and intervention phases)
 Participant is subsequently diagnosed with a proven
cause for secondary constipation, e.g. Parkinson’s
disease or bowel obstruction
 Participant requires new medication with proven
effects on bowel function, e.g. opioids
 Participant develops significant intercurrent illness
precluding participation
 Participant requires surgery or other intervention
(other than minor ops) during treatment or follow-
up phase
 Participant develops acute psychological problem
causing safety concern
 Adverse events secondary to therapy (bleeding, anal
fissure, ulceration, pain, bowel perforation) – relative
indications for withdrawal depending on the views of
the patient and physician. (Note: bowel perforation is
an absolute indication for withdrawal)
 Elective withdrawal
Loss to follow-up (no further interventions or follow-up
data collected)
 During follow-up (up to 12 months), participants
may be withdrawn from the trial if they become lost
to follow-up (LTFU) after at least three failed
attempts by research staff to make contact via two
different methods (e.g. telephone and letter)
 Participant chooses to withdraw and does not wish
to participate in follow-up data collection
 Death or significant incapacity making follow-up
data collection impossible
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End of study definition
The end of study is defined as the last patient last visit.
The sponsor, REC and local R&D departments will be
informed of end of study and site closure and archiving
procedures initiated.
Criteria for early termination
If the Data Monitoring and Ethics Committee (DMEC),
Programme Steering Committee (PSC), Research Ethics
Committee (REC) or sponsor determine that it is within
the best interests of the participants or trial to terminate
the study, written notification will be given to the chief
investigator (CI). This may be due to, but not limited to:
serious safety concerns, serious breaches, acts of fraud,
critical findings or persistent noncompliance that nega-
tively affects patient safety or data integrity. If the study
is terminated participants will be returned to the NHS
normal follow-up and routine care.
Qualitative interviews
The purpose of this qualitative enquiry is to complement
the quantitative study of TAI. A phenomenological
methodology will be employed and qualitative data will
be collected in parallel with the quantitative study. Par-
ticipants will be recruited separately from the quantita-
tive study, with separate PISs and consent processes.
Sampling
A purposive sample of approximately 35 patients will
be invited to interview upon completion of irrigation
training and then again at 6 months. Participants do
not have to participate in both sets of interviews; a
separate set of patients can be interviewed at
6 months. Recruitment can be extended if data satur-
ation is not accomplished by the 35th patient. Data
saturation is defined as the point at which no new or
relevant themes emerge. Inclusion and exclusion cri-
teria are as above. Participants will be selected from a
sampling grid of potential interviewees to reflect a
range of ages, geographical locations and, where pos-
sible, other pertinent attributes such as ethnicity and
gender. An approximately equal number of patients
will be selected from each trial arm as follows:
 Seventeen patients undergoing low-volume anal
irrigation and 18 patients undergoing high-volume
irrigation and including those who discontinue early
(before 3 months), later (3–5 months), those who
continue with their allocated treatment, and those
who switch
 In addition, approximately 10 health professionals
involved in delivering the treatment will be
interviewed. These health care professionals will be
evenly distributed across participating centres
Data collection
All participants will be told that they might be invited
for interview when they are initially informed about
the study. Participants will be contacted by a member
of the clinical team and if interested in being inter-
viewed a separate PIS will be provided. Participants
will be offered a semistructured interview in a clinic
room or in their own home according to their prefer-
ence, and will be offered a chaperone to be present if
they would prefer. Professionals will be interviewed in
a clinic setting. Following written consent, the inter-
views will be recorded on a digital dictaphone and
transcribed into a pseudonymised (alphanumeric code)
text document. Interviews will be conducted by an ex-
perienced qualitative researcher working within the
wider CapaCiTY research programme. A clinical re-
search fellow at UHND and/or a health research
methodologist at Durham University will conduct in-
terviews recruited from the Durham site.
Interviews will explore health professionals’ and partic-
ipants’ experiences of recruitment, individual interven-
tions, their training and delivery, and patients’ views
about outcome measures. A topic guide for each of the
interviews and focus groups, informed by the existing
literature and our patient advisors, will be developed.
Timing
Patients will be invited to one-to-one interviews on
completion of training and will be interviewed a max-
imum of 4 weeks after training to maximise recall. Pa-
tients will be recalled up to 6 months after training and
offered an interview. The patients interviewed at base-
line do not have to be the same as those interviewed up
to 6 months. Interviews will be conducted throughout to
capture relatively early and later experiences and percep-
tions of the interventions.
Analysis
Interviews will be digitally recorded, anonymised,
transcribed verbatim and analysed using a thematic
analysis and NVivo8 software (QSR International Ltd.,
Warrington, UK) for data management. Data analysis
will be developed as outlined by Fereday and Muir-
Cochrane [58] in the first instance by mapping key con-
cepts derived from the transcripts (‘charting’) and extract-
ing emergent themes from the transcripts. Professor
Norton will coordinate and conduct analysis, while for the
purposes of Christopher Emmett’s MD, independent ana-
lysis will be conducted by CE and Dr. Helen Close. Emer-
gent themes, together with captured observational data,
will form the basis of analytical interpretation. Data will
be handled in a confidential manner at all times, and only
transferred on encrypted media or via secure electronic
transfer.
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Statistical considerations
Sample size
PAC-QOL is a 28-item disease-specific measure, with
each item scored 0–4, and providing an aggregate score
0– [34]. Superiority of either low-volume or high-
volume anal irrigation is demonstrated by a 10% scale
difference (or more), or 0.4, with a variance estimate
conservatively set at SD = 1 from the published medical
literature [59]. To detect an effect size of 0.4 (mean/
SD = 0.4) between the two groups with 90% power
and 5% significance at 3 months requires 133 patients
per arm, and 266 total. Allowing for an anticipated
10% loss to follow-up (LTFU), then 300 patients will
be recruited.
Clinical outcomes
A full analysis plan will be signed off before allocation
codes are made available to the statistician. The codes
will not indicate which treatment arm is which so that
as far as possible the statistician will remain blind to al-
location throughout the analysis. All analyses will be by
the intention-to-treat principle. The primary outcome
will be PAC-QOL as a continuous variable, analysed at
3 months while the quarantine period is in effect. The
proportion of patients continuing with the initial therapy
system will be recorded, and the PAC-QOL scores will
be analysed using a linear mixed model with a random
effect for centre and fixed effects for intervention, trial
stratification variables (participants are stratified by sex
and women by centre) and baseline PAC-QOL. Second-
ary outcomes will be analysed using the principles out-
lined above for the primary outcome.
Exploratory modelling will be conducted for baseline
characteristics: measures of chronic pain, autonomic,
joint hypermobility, cognitive, behavioural and mood
variables share a common hypothesis that they are detri-
mental to the success of all treatments, i.e. they perpetu-
ate illness in spite of therapy. We will investigate a
maximum of three interactions between treatment and
baseline characteristics. These will be described in the
SAP a priori. Appropriate regression models, including
interaction terms, will be developed to determine the in-
fluence of these pretreatment characteristics on the suc-
cess of treatments in all WPs.
Life table data for any irrigation will be presented by
initial therapy and for specific therapy from date of com-
mencement. Survival analysis will be presented using
Kaplan-Maier analysis and adjusted using Cox regres-
sion. Exploratory analysis will be considered to identify
characteristics of subgroups with greatest persistent
benefit from irrigation. These will be described in the
SAP a priori.
Analysis will be performed using proprietary software,
(Stata Corp., College Station, TX, USA). P < 0.05 will be
taken to indicate statistical significance. No analyses will
be conducted until an analysis plan has been written,
reviewed by an independent statistician and signed off.
Multiple imputation will be considered to address
missing covariate values. Details of any imputation to be
performed will be described in the SAP which will be
finalised after initial checks on completeness of the data
but before performing any analysis or unblinding of the
data.
Health economic outcomes
The patient journal will facilitate the capture of health
economic data which will be recorded on the CRF at
each visit. This will be combined with the initial cost of
the device and weekly consumables.
Within-trial stochastic analysis will compare the cost/
success and cost/quality-adjusted life year (QALY) of
anal irrigation. Patient-level cost-effectiveness analysis
will use standard bootstrapping methods to generate
cost-effectiveness acceptability curves exploring value for
money. Within-cohort combined stochastic/probabilistic
epidemiological models will be used to assess irrigation
and surgery options, exploring relative effectiveness and
cost-effectiveness according to patient characteristics.
Cost-effectiveness models that extrapolate beyond 3–6
months’ duration are problematic in adult constipation,
as subsequent care and outcomes are contingent upon
subsequent care received and the underlying disease
process. However, the programme of WPs, and inclusion
of time to failure data capture, provides a unique oppor-
tunity to construct probabilistic models exploring opti-
mal pathways from effectiveness and cost-effectiveness
perspectives.
Since patients will (within the CapaCiTY programme)
be followed along a pathway that includes a series of
steps of care, it will be possible to construct costs and
outcomes for a range of patient pathways providing
comparative longer-term cost-effectiveness estimates.
Patient-level data from recruitment through the various
WPs will be used to construct pragmatic, probabilistic
models to explore optimal pathways from effectiveness
and cost-effectiveness perspectives.
Analyses from NHS and societal perspectives will be
supported by recording relevant resource use during
each WP, and a common panel of outcomes. Adjustment
for time preference will be at the socially accepted rate
for cost-effectiveness analyses (currently 3.5%/annum for
costs and benefits).
Data analysis for MD thesis
The study will form the basis of a thesis for an MD at
Durham University by a research fellow (Christopher
Emmett) at University Hospital of North Durham
(UHND). Patients recruited at UHND and the Royal
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Victoria Infirmary, Newcastle upon Tyne up to 1
October 2016 (estimated 50 patients) will be analysed in
this thesis, including those recruited to the qualitative
arm of the study at this site. These patients will have a
minimum of 3 months of study data. The release of data
from the UHND and Newcastle sites for this purpose
has been approved by the chief investigator (CI) on the
condition that it may be used for thesis examination but
is not published or made publically available until the
CapaCiTY programme results are published in full. The
qualitative data from the Durham site may be published
separately as agreed.
Laboratories (if applicable)
Serum pregnancy testing will be performed by local
NHS biochemistry laboratories.
Products, devices, techniques and tools
Devices
There are no investigative medicinal products or investi-
gative devices under study. The following is a list of all
devices routinely used in clinical care and none are spe-
cific to the research itself. All are CE-marked and ap-
proved for use in the UK.
1. Disposable proctoscope (supplier as local NHS
practice). This will be commonly be used as part of
clinical examination at baseline and is also used to
introduce balloon catheters into the rectum during
INVEST
2. High-resolution anorectal manometry (HRAM
system +Unisensor HRAM catheter (200 uses) and
balloons, software, cables, calibration kit, isolation
transformer and laptop. Insertion and use are
outlined under the ‘Interventions’ section (equipment
provided at study outset)
3. Standard anorectal manometry catheter, balloons,
software, cables, calibration kit and associated
equipment; standard equipment in many NHS
centres for performing anorectal physiology. Can be
used as an alternative where high-resolution
manometry is not available (part of INVEST – see
above)
4. Balloon catheters for balloon expulsion test (part of
INVEST – see above)
5. Radio-opaque markers for colonic transit study:
various suppliers (part of INVEST – see above)
6. Standard departmental X-ray equipment (part of
INVEST – see above)
7. Peristeen™ anal irrigation system (Coloplast),
Qufora® Balloon™/Qufora Toilet anal irrigation
systems (MBH-International): established anal
irrigation systems available on prescription in NHS
practice. Other systems with the same mechanism
of action may also be used (dependent on local
funding and prescribing arrangements)
8. Qufora® Mini anal irrigation system (MBH-
International): established anal irrigation system
available on prescription in NHS practice
All devices are maintained, calibrated and serviced ac-
cording to standard NHS policies and procedures ac-
cording to manufacturer’s guidance. Training on devices
is provided by the supplier’s representatives. Additional
study SOPs and training will be provided to ensure
standardisation across sites, but will be in line with
current NHS standard practice.
Data collection tools
The permissions/licenses to use the below instruments
have been sought on the understanding that sites are
permitted to utilise these within this study only, they will
be provided to sites as part of the CRF for the study:
 PAC-QOL score: from MAPI Research Trust
 PAC-SYM score: from MAPI Research Trust
 EQ-5D-5 L: from EuroQol
The below-listed questionnaire-based tools are free to
use within the public domain and will be provided to
sites as part of the CRFs for the study.
 Depression, anxiety and somatisation modules of the
Patient Health Questionnaire
 Illness Perception Questionnaire
 Composite Rome III/Cleveland Clinic Constipation
Questionnaire: free to use
 Brief, chronic pain, autonomic and joint
hypermobility: free to use
 Negative perfectionism
 Avoidant and ‘all or nothing’ behaviour subscales of
the Behavioural Response to Illness Questionnaire
Safety reporting
Adverse events (AEs)
An AE is any untoward medical occurrence in a subject
to whom an intervention has been administered, includ-
ing occurrences which are not necessarily caused by, or
related to, that intervention. An AE can, therefore, be
any unfavourable and unintended sign (including an ab-
normal laboratory finding), symptom or disease tempor-
arily associated with study activities.
Notification and reporting adverse events or reactions
The anal irrigation systems are in widespread and estab-
lished clinical use throughout the NHS with known AEs
occurring (22%) being mostly low grade and reversible.
All trial interventions are as per the standard care
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provided within the NHS for CC. Related AEs will be re-
corded on the CRF. Serious adverse events (SAEs) will
be recorded on the CRF and in the medical notes to en-
able assessment and reporting in line with sponsor and
regulatory requirements. Causality will be at the discre-
tion of the health care provider (e.g. research nurse,
physiotherapist, PI or delegated member of team). These
will be assessed as outlined below.
Trial participants will be advised to seek medical sup-
port from their GP for any unrelated signs, symptoms or
disease or aggravation of underlying symptoms.
Serious adverse event (SAE)
In other research other than CTIMPs, a SAE is defined
as an untoward occurrence that:
1. Results in death
2. Is life-threatening.
3. Requires hospitalisation or prolongation of existing
hospitalisation
4. Results in persistent or significant disability or
incapacity
5. Consists of a congenital anomaly or birth defect, or
6. Is otherwise considered medically significant by the
investigator
An SAE occurring to a research participant should be
reported to the sponsor and Main Research Ethics
Committee (MREC) where, in the opinion of the CI, the
event was:
 Related – that is, it resulted from administration of
any of the research procedures, and
 Unexpected – that is, the type of event is not listed
in the protocol as an expected occurrence (see
Additional file 3)
Notification and reporting of SAEs
Serious adverse events (SAEs) that are considered to be
‘related’ and ‘unexpected’ are to be reported to the spon-
sor within 24 h of learning of the event and to the
MREC within 15 days in line with the required time-
frame. For further guidance on this matter, please refer
to the HRA website and Joint Research Management
Office (JRMO) SOPs.
Expected SAEs
The following SAEs are expected to occur rarely in this
patient population and will not be reported:
 Hospital admission for exacerbation of constipation
symptoms including impaction
 Hospital admission for unrelated elective surgical
procedures or accidental injury
Urgent safety measures
The CI may take urgent safety measures to ensure the
safety and protection of the clinical trial subjects from
any immediate hazard to their health and safety. The
measures should be taken immediately. In this instance,
the approval of the REC prior to implementing these
safety measures is not required. However, it is the re-
sponsibility of the CI to inform the sponsor and the
MREC (via telephone) of this event immediately.
The CI has an obligation to inform both the MREC in
writing within 3 days, in the form of a substantial
amendment. The sponsor, JRMO, must be sent a copy of
the correspondence with regards to this matter. For fur-
ther guidance on this matter, please refer to the HRA
website and JRMO SOPs.
Annual safety reporting
The CI will send the Annual Progress Report to the
MREC using the HRA template (the anniversary date is
the date on the MREC ‘favourable opinion’ letter from
the MREC) and to the sponsor. Please see the HRA web-
site and JRMO SOP for further information.
Overview of the safety reporting responsibilities
The CI/PI has the overall responsibility for oversight of
safety reporting. The CI/PI also has a duty to ensure that
safety monitoring and reporting is conducted in accord-
ance with the sponsor’s requirements.
Monitoring and auditing
The PCTU quality assurance (QA) manager will conduct
a study risk assessment in collaboration with the CI.
Based on the risk assessment, an appropriate study mon-
itoring and auditing plan will be produced according to
PCTU SOPs. This monitoring plan will be authorised by
the sponsor before implementation. Any changes to the
monitoring plan must be agreed by the PCTU QA man-
ager and the sponsor.
Audit definition:
‘A systematic and independent examination of trial-
related activities and documents to determine whether
the evaluated trial-related activities we reconducted,
and the data were recorded, analysed and accurately
reported according to the protocol, sponsor’s SOPs,
Good Clinical Practice (GCP) and the applicable
regulatory requirement(s).’
A study may be identified for audit by any method
listed below:
1. A project may be identified via the risk assessment
process.
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2. An individual investigator or department may
request an audit.
3. A project may be identified via an allegation of
research misconduct or fraud or a suspected breach
of regulations
4. Projects may be selected at random. The Department
of Health states that trusts should be auditing a
minimum of 10% of all research projects
5. Projects may be randomly selected for audit by an
external organisation
Internal audits may be conducted by a sponsor’s or
a funder’s representative according to JRMO/NIHR
SOPs.
Safety considerations
Patients recruited who have not had previous INVEST
procedures conducted within the last 12 months will
undergo a radiological procedure (whole gut transit)
using ionising radiation as outlined above. The average
dose of this procedure (approximately 0.1 mSv) is
equivalent to about 2.5 weeks’ annual background radi-
ation dose from living in the UK Further, these investiga-
tions would be carried out in routine clinical practice in
many centres for patients at the same point as recruit-
ment to this study.
Regarding the intervention, anal irrigation is associated
with a very low incidence of bowel perforation, as well
as other side effects (bleeding, pain, ulceration, painful
haemorrhoids, anal fissure). Patients will be counselled
regarding these risks as part of the process of informed
consent. In addition, they will be trained in the correct
use of the device prior to commencing therapy. All re-
lated AEs and all SAEs will be recorded and therapy sus-
pended while these are investigated.
Trial committees
The project will be under the auspices of the CI and the
PCTU. The project will be overseen by a Programme
Steering Committee (PSC).
The composition and responsibilities of the PSC will
comply with the NIHR guidance and PCTU SOP on
Trial Oversight Committees. The role of the PSC is to
provide overall supervision of the study on behalf of the
sponsor and funder to ensure that study is conducted in
accordance with the principles of Good Clinical Practice
(GCP) relevant regulations.
The responsibilities of the PSC will include:
 Ensuring that the views of users and carers are
taken into consideration
 Advising on the trial protocol
 Advising on changes in the protocol based on
considerations of feasibility and practicability
 Assisting in resolving problems brought to it by the
Programme Management Group (PMG)
 Monitoring the progress of the trial and adherence
to protocol and milestones
 Considering new information of relevance from
other sources
 Considering and acting on the recommendations of
the Data Monitoring Committee (DMC), sponsor
and/or MREC
 Review initial reports and papers for publication
The PSC will meet to review the protocol before the
start of the programme and then soon after the first par-
ticipants are recruited and either meet or teleconference
every 6 months thereafter throughout the lifetime of the
programme.
Representatives of the trial sponsor and the funder will
be invited to attend.
A PMG made up of core staff from the coordinating
centres and the PCTU will meet monthly initially during
study set-up and then less frequently, every 2 months. The
PMG will be responsible for day-to-day project delivery
across participating centres, and will report to the PSC.
An independent Data Monitoring and Ethics Committee
(DMEC) will be convened. The DMEC will meet at least
4 weeks prior to the PSC to enable recommendations to be
fed forward.
A DAMOCLES charter will be adopted, and the pro-
ject team will provide the DMEC with a comprehensive
report, the content of which should be agreed in ad-
vance by the chair of the DMEC and follow guidelines
set out in the charter.
A Constipation Research Advisory Group (CRAG) will
be formed as part of a well-developed Patient and Public
Involvement (PPI) strategy at QMUL. This advisory
group will comprise eight patients and two lay members
derived from London and Durham. This group will have
geographical diversity (north and south) and a disease-
appropriate demographic (eight women, two men). The
CRAG will be involved in:
 Review of PISs, booklets, diaries and advertising/
marketing materials
 Project management by representation on the PSC
 Parallel qualitative analysis
 Dissemination of results and lay summaries
 Presentations at local research events
 Patient focus groups and workshops
Project management
Local coordination
Each participating centre will identify a site-specific PI
who will nominate a local contact for that centre (this
may be themselves). The PI and local contact will:
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 Be familiar with the trial
 Liaise with the PCTU and the PMG
 Ensure that all staff involved in the trial are
informed about the trial and have received
requisite training
 Ensure that mechanisms for recruitment of eligible
participants, including the availability of participant
information and data collection tools, are in place;
monitor their effectiveness and discuss the reasons
for nonrecruitment with relevant staff
 Ensure that site staff collect necessary trial data and
perform quality checks
 Notify the CI of any SAE’s
 Make data available for verification, audit and
inspection processes as necessary, and respond to
requests for documentation and data required for
centralised monitoring
 Ensure that the confidentiality of all information
about trial participants is respected by all persons
Site initiation and training
A central study launch meeting and/or site initiation will
be conducted with each site. This will include training in
the trial protocol and SOPs, such as data collection, ran-
domisation and taking informed consent. Evidence of
appropriate training, local approvals and essential docu-
mentation will be required before participants being en-
rolled at each site. Training will be documented on
training logs.
Project timetable, milestones and projected recruitment
The PMG will be responsible for monitoring adherence
to the study timelines and expected recruitment rates.
Regular reports will be produced to enable deviations
from the project plan to be identified and contingencies
planned, discussed and executed in a timely fashion.
Projected recruitment dates are:
1 Aug 2015: first participant
31 Apr 2016: 100 participants
30 Nov 2016: 200 participants
30 Jun 2017: 300 participants
30 Oct 2017: last patient intervention
31 Apr 2018: 3-month primary endpoint
31 Oct 2018: 12-month secondary endpoint
Discussion
The CapaCiTY 02 study is a large and potentially very
rich study in terms of hypothesis-testing and generating
robust evidence. As previously noted, its primary aim of
establishing superiority of one system of irrigation over
another will provide valuable information that can be
used to guide the choice of therapy in patients with CC.
Additionally, the study aims to explore health economic
outcomes, and will also evaluate the association between
pretreatment baseline characteristics (e.g. psychological
profile, joint hypermobility, colonic transit, anorectal
physiology) and treatment success. Alongside these ele-
ments, a qualitative component of the study will explore
the lived experiences of patients and health care profes-
sionals who are using irrigation, or training patients in
its use.
The multisite nature of the study, along with the broad
range of outcome measures being employed, could po-
tentially lead to several practical challenges in imple-
menting the study protocol. Attempts have been made
to anticipate and address these before commencing
study recruitment. Prestudy site feasibility questionnaires
were circulated to all sites wishing to participate, and
these were used to identify the key components of irriga-
tion training and treatment at each site. The training
process described in this protocol aims to be as applic-
able as possible to as broad a range of sites as feasible,
without causing the study sites to make significant alter-
ations to their standard practice.
The protocol also aims to be flexible as regards pre-
treatment investigations. These have been limited to
anorectal physiology and a transit study (see section
above: ‘INVEST’). It was felt that these provided im-
portant information necessary for characterising pa-
tients before starting treatment, thereby allowing
analysis of the relationship between pretreatment
characteristics and treatment success. It was decided,
as few sites had access to HRAM, that standard man-
ometry was sufficient for the purposes of this study.
This increased participation by allowing sites not in
possession of the necessary high-resolution equipment
to still recruit to the study.
It is recognised that the study design has several limi-
tations. From a methodological perspective, the fact that
neither participant nor assessor blinding was feasible
(due to the nature of the treatment and the nature of
the outcome data being collected), leads to the possibil-
ity of performance bias and reporting bias, as both
participants and assessors will (consciously or uncon-
sciously) have particular preconceived ideas about the
likely efficacy of each system. Attempts have been made,
from a methodological and operational perspective, to
limit the impact of this. The fact that every patient re-
ceives treatment is important, as it is a reasonable as-
sumption that the placebo effect for each system is
similar, thereby meaning that any observed difference
between systems is a genuine one. Additionally, the op-
tion of switching systems after 3 months is designed to
allow participants who have not had success with their
original system to try the other one. This means that pa-
tients do not spend too long on ineffective treatment,
and also allows longer-term data (more than 3 months)
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to evaluate the effectiveness of the treatment as a whole
in the long term.
As can be seen from the ‘Trial status’ section below,
recruitment nationally has fallen below the planned rate
of recruitment. Several reasons for low recruitment have
been identified through discussions with participating
sites; these are mainly the result of variation in local
practice (making the protocol difficult to implement), as
well as service pressures and the pressure on research
teams from doing more than one study in the CapaCiTY
programme. This highlights the difficulties in imple-
menting multisite studies, and even though attempts
were made before study commencement to ensure suffi-
cient flexibility in the proposed study design, problems
have nonetheless been encountered.
Since recruitment has opened, recruitment rates at
each study site are monitored and monthly meetings are
held to discuss progress and to identify problems at an
early stage. Teleconferences have been held with recruit-
ing sites in order to discuss and resolve barriers to
recruitment.
Trial status
As of 31 August 2016, the study has seven sites open to
recruitment. The first patient was enrolled on 15
October 2015. Currently, 39 patients have been screened
and 22 randomised. Of these, two have withdrawn
(elective withdrawal – no reason given).
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